Page 400 - Williams Hematology ( PDFDrive )

374 Part V: Therapeutic Principles Chapter 23: Hematopoietic Cell Transplantation 375

56. Siena S, Bregni M, Brando B, et al: Circulation of CD34+ hematopoietic stem cells in 84. Barker JN, Scaradavou A, Stevens CE: Combined effect of total nucleated cell dose and
the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement HLA match on transplantation outcome in 1061 cord blood recipients with hemato-
by intravenous recombinant human granulocyte-macrophage colony-stimulating fac- logic malignancies. Blood 115:1843–1849, 2010.
tor. Blood 74:1905–1914, 1989. 85. Ponce DM, Gonzales A, Lubin M, et al: Graft-versus-host disease after double-unit
57. Chao NJ, Schriber JR, Grimes K, et al: Granulocyte colony-stimulating factor “mobi- cord blood transplantation has unique features and an association with engrafting
lized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery unit-to-recipient HLA match. Biol Blood Marrow Transplant 19:904–911, 2013.
after high-dose chemotherapy. Blood 81:2031–2035, 1993. 86. Avery S, Shi W, Lubin M, et al: Influence of infused cell dose and HLA match on
58. Becker PS, Wagle M, Matous S, et al: Spontaneous splenic rupture following adminis- engraftment after double-unit cord blood allografts. Blood 117:3277–3285; quiz 3478,
tration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic 2011.
donor of peripheral blood stem cells. Biol Blood Marrow Transplant 3:45–49, 1997. 87. Wagner JE, Barker JN, DeFor TE, et al: Transplantation of unrelated donor umbilical
59. Falzetti F, Aversa F, Minelli O, et al: Spontaneous rupture of spleen during peripheral cord blood in 102 patients with malignant and nonmalignant diseases: Influence of
blood stem-cell mobilisation in a healthy donor. Lancet 353:555, 1999. CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood
60. Storek J, Dawson MA, Maloney DG: Normal T, B, and NK cell counts in healthy donors 100:1611–1618, 2002.
at 1 year after blood stem cell harvesting. Blood 95:2993–2994, 2000. 88. Wagner JE Jr, Eapen M, Carter S, et al: One-unit versus two-unit cord-blood transplan-
61. Duong HK, Savani BN, Copelan E, et al: Peripheral blood progenitor cell mobilization tation for hematologic cancers. N Engl J Med 371:1685–1694, 2014.
for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the 89. Sideri A, Neokleous N, Brunet De La Grange P, et al: An overview of the progress on
American Society for Blood and Marrow Transplantation. Biol Blood Marrow Trans- double umbilical cord blood transplantation. Haematologica 96:1213–1220, 2011.
plant 20:1262–1273, 2014. 90. Gutman JA, Turtle CJ, Manley TJ, et al: Single-unit dominance after double-unit umbil-
62. Calandra G, McCarty J, McGuirk J, et al: AMD3100 plus G-CSF can successfully ical cord blood transplantation coincides with a specific CD8+ T-cell response against
mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple the nonengrafted unit. Blood 115:757–765, 2010.
myeloma patients previously failing mobilization with chemotherapy and/or cytokine 91. Delaney C, Heimfeld S, Brashem-Stein C, et al: Notch-mediated expansion of human
treatment: Compassionate use data. Bone Marrow Transplant 41:331–338, 2008. cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 16:232–
63. Devine SM, Vij R, Rettig M, et al: Rapid mobilization of functional donor hematopoi- 236, 2010.
etic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interac- 92. de Lima M, McNiece I, Robinson SN, et al: Cord-blood engraftment with ex vivo mes-
tion. Blood 112:990–998, 2008. enchymal-cell coculture. N Engl J Med 367:2305–2315, 2012.
64. Lundqvist A, Smith AL, Takahashi Y, et al: Differences in the phenotype, cytokine gene 93. Cutler C, Multani P, Robbins D, et al: Prostaglandin-modulated umbilical cord blood
expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor com- hematopoietic stem cell transplantation. Blood 122:3074–3081, 2013.
pared with G-CSF. J Immunol 191:6241–6249, 2013. 94. Risdon G, Gaddy J, Broxmeyer HE: Allogeneic responses of human umbilical cord
65. Mendez-Ferrer S, Lucas D, Battista M, et al: Haematopoietic stem cell release is regu- blood. Blood Cells 20:566–570; discussion 571–572, 1994.
lated by circadian oscillations. Nature 452:442–447, 2008. 95. Renard C, Barlogis V, Mialou V, et al: Lymphocyte subset reconstitution after unrelated
66. Lucas D, Battista M, Shi PA, et al: Mobilized hematopoietic stem cell yield depends on cord blood or bone marrow transplantation in children. Br J Haematol 152:322–330,
species-specific circadian timing. Cell Stem Cell 3:364–366, 2008. 2011.
67. Shi PA, Isola LM, Gabrilove JL, et al: Prospective cohort study of the circadian rhythm 96. Herrera AF, Soriano G, Bellizzi AM, et al: Cord colitis syndrome in cord-blood stem-
pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulat- cell transplantation. N Engl J Med 365:815–824, 2011.
ing factor mobilization. Stem Cell Res Ther 4:30, 2013. 97. Bhatt AS, Freeman SS, Herrera AF, et al: Sequence-based discovery of Bradyrhizobium
68. Schmitz N, Linch DC, Dreger P, et al: Randomised trial of filgrastim-mobilised periph- enterica in cord colitis syndrome. N Engl J Med 369:517–528, 2013.
eral blood progenitor cell transplantation versus autologous bone-marrow transplanta- 98. Milano F, Shulman HM, Guthrie KA, et al: Late-onset colitis after cord blood transplan-
tion in lymphoma patients. Lancet 347:353–357, 1996. tation is consistent with graft-versus-host disease: Results of a blinded histopathologi-
69. Vose JM, Sharp G, Chan WC, et al: Autologous transplantation for aggressive cal review. Biol Blood Marrow Transplant 20:1008–1013, 2014.
non-Hodgkin’s lymphoma: Results of a randomized trial evaluating graft source and 99. Shimoji S, Kato K, Eriguchi Y, et al: Evaluating the association between histologi-
minimal residual disease. J Clin Oncol 20:2344–2352, 2002. cal manifestations of cord colitis syndrome with GVHD. Bone Marrow Transplant
70. Vellenga E, van Agthoven M, Croockewit AJ, et al: Autologous peripheral blood stem 48:1249–1252, 2013.
cell transplantation in patients with relapsed lymphoma results in accelerated haemato- 100. Ash RC, Horowitz MM, Gale RP, et al: Bone marrow transplantation from related
poietic reconstitution, improved quality of life and cost reduction compared with bone donors other than HLA-identical siblings: Effect of T cell depletion. Bone Marrow
marrow transplantation: The Hovon 22 study. Br J Haematol 114:319–326, 2001. Transplant 7:443–452, 1991.
71. Toh HC, Sun L, Soe Y, et al: G-CSF induces a potentially tolerant gene and immunophe- 101. Aversa F, Velardi A, Tabilio A, et al: Haplo-identical stem cell transplantation in leuke-
notype profile in T cells in vivo. Clin Immunol 132:83–92, 2009. mia. Blood Rev 15:111–119, 2001.
72. Anasetti C, Logan BR, Lee SJ, et al: Peripheral-blood stem cells versus bone marrow 102. Aversa F, Tabilio A, Velardi A, et al: Treatment of high-risk acute leukemia with
from unrelated donors. N Engl J Med 367:1487–1496, 2012. T-cell-depleted stem cells from related donors with one fully mismatched HLA haplo-
73. Friedrichs B, Tichelli A, Bacigalupo A, et al: Long-term outcome and late effects in type. N Engl J Med 339:1186–1193, 1998.
patients transplanted with mobilised blood or bone marrow: A randomised trial. Lan- 103. Aversa F: Haplo-identical haematopoietic stem cell transplantation for acute leukaemia
cet Oncol 11:331–338, 2010. in adults: Experience in Europe and the United States. Bone Marrow Transplant 41:473–
74. Mielcarek M, Storer B, Martin PJ, et al: Long-term outcomes after transplantation of 481, 2008.
HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus 104. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural killer cell allore-
bone marrow. Blood 119:2675–2678, 2012. activity in mismatched hematopoietic transplants. Science 295:2097–2100, 2002.
75. Couban S, Simpson DR, Barnett MJ, et al: A randomized multicenter comparison of 105. Aversa F, Terenzi A, Tabilio A, et al: Full haplotype-mismatched hematopoietic stem-
bone marrow and peripheral blood in recipients of matched sibling allogeneic trans- cell transplantation: A phase II study in patients with acute leukemia at high risk of
plants for myeloid malignancies. Blood 100:1525–1531, 2002. relapse. J Clin Oncol 23:3447–3454, 2005.
76. Holtick U, Albrecht M, Chemnitz JM, et al: Bone marrow versus peripheral blood allo- 106. Luznik L, Jalla S, Engstrom LW, et al: Durable engraftment of major histocompatibil-
geneic haematopoietic stem cell transplantation for haematological malignancies in ity complex-incompatible cells after nonmyeloablative conditioning with fludarabine,
adults. Cochrane Database Syst Rev 4:Cd010189, 2014. low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood
77. Zhang H, Chen J, Que W: Allogeneic peripheral blood stem cell and bone marrow 98:3456–3464, 2001.
transplantation for hematologic malignancies: Meta-analysis of randomized controlled 107. O’Donnell PV, Luznik L, Jones RJ, et al: Nonmyeloablative bone marrow transplanta-
trials. Leuk Res 36:431–437, 2012. tion from partially HLA-mismatched related donors using posttransplantation cyclo-
78. Chang YJ, Weng CL, Sun LX, et al: Allogeneic bone marrow transplantation compared phosphamide. Biol Blood Marrow Transplant 8:377–386, 2002.
to peripheral blood stem cell transplantation for the treatment of hematologic malig- 108. Brunstein CG, Fuchs EJ, Carter SL, et al: Alternative donor transplantation after reduced
nancies: A meta-analysis based on time-to-event data from randomized controlled tri- intensity conditioning: Results of parallel phase 2 trials using partially HLA-mis-
als. Ann Hematol 91:427–437, 2012. matched related bone marrow or unrelated double umbilical cord blood grafts. Blood
79. Bensinger WI, Martin PJ, Storer B, et al: Transplantation of bone marrow as compared 118:282–288, 2011.
with peripheral-blood cells from HLA-identical relatives in patients with hematologic 109. Kanakry JA, Kasamon YL, Bolanos-Meade J, et al: Absence of post-transplantation
cancers. N Engl J Med 344:175–181, 2001. lymphoproliferative disorder after allogeneic blood or marrow transplantation using
80. Gragert L, Eapen M, Williams E, et al: HLA match likelihoods for hematopoietic stem- post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol
cell grafts in the U.S. registry. N Engl J Med 371:339–348, 2014. Blood Marrow Transplant 19:1514–1517, 2013.
81. Arcese W, Rocha V, Labopin M, et al: Unrelated cord blood transplants in adults with 110. van Rood JJ, Loberiza FR Jr, Zhang MJ, et al: Effect of tolerance to noninherited mater-
hematologic malignancies. Haematologica 91:223–230, 2006. nal antigens on the occurrence of graft-versus-host disease after bone marrow trans-
82. Gluckman E, Broxmeyer HA, Auerbach AD, et al: Hematopoietic reconstitution in plantation from a parent or an HLA-haplo-identical sibling. Blood 99:1572–1577, 2002.
a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA- 111. Stern M, Ruggeri L, Mancusi A, et al: Survival after T cell-depleted haplo-identical stem
identical sibling. N Engl J Med 321:1174–1178, 1989. cell transplantation is improved using the mother as donor. Blood 112:2990–2995, 2008.
83. Gluckman E, Ruggeri A, Volt F, et al: Milestones in umbilical cord blood transplanta- 112. Wang Y, Chang YJ, Xu LP, et al: Who is the best donor for a related HLA haplotype-
tion. Br J Haematol 154:441–447, 2011. mismatched transplant? Blood 124:843–850, 2014.

Kaushansky_chapter 23_p0353-0382.indd 375 9/19/15 12:47 AM